Zealand Pharma A/S (ZLDPF)
OTCMKTS · Delayed Price · Currency is USD
61.06
+2.66 (4.55%)
Jul 24, 2025, 11:24 AM EDT
Zealand Pharma Revenue
Zealand Pharma had revenue of 8.09M DKK in the quarter ending March 31, 2025, a decrease of -46.37%. This brings the company's revenue in the last twelve months to 55.69M, down -83.82% year-over-year. In the year 2024, Zealand Pharma had annual revenue of 62.69M, down -81.71%.
Revenue (ttm)
55.69M DKK
Revenue Growth
-83.82%
P/S Ratio
518.33
Revenue / Employee
166.25K DKK
Employees
335
Market Cap
4.18B USD
Revenue Chart
* This company reports financials in DKK.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 62.69M | -280.10M | -81.71% |
Dec 31, 2023 | 342.79M | 238.80M | 229.65% |
Dec 31, 2022 | 103.99M | -4.56M | -4.20% |
Dec 31, 2021 | 108.55M | -83.46M | -43.47% |
Dec 31, 2020 | 192.00M | 150.67M | 364.52% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo, Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Elite Pharmaceuticals | 84.04M |
Glass House Brands | 215.62M |
Northwest Biotherapeutics | 1.47M |
American Oncology Network | 1.76B |
Silence Therapeutics | 27.70M |
Zealand Pharma News
- 7 days ago - Zealand Pharma major shareholder announcement: Van Herk Investments B.V. - GlobeNewsWire
- 5 weeks ago - Zealand Pharma Obesity Therapy Shows Positive Trial Results - Market Watch
- 5 weeks ago - Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutide - GlobeNewsWire
- 7 weeks ago - Zealand Pharma increases its share capital as a result of the exercise of employee warrants - GlobeNewsWire
- 7 weeks ago - Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome - GlobeNewsWire
- 2 months ago - Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons - GlobeNewsWire
- 2 months ago - European stocks edge higher after Trump delays 50% tariffs on EU - CNBC
- 2 months ago - European stocks recover after Trump delays EU tariffs in hopes of deal - Reuters